Quantcast

Latest Tardive dyskinesia Stories

2010-03-05 12:33:00

Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal study Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD). Data from this study demonstrated that after an 80-week treatment period, subjects treated with Xenazine experienced a statistically significant...

2009-12-21 13:30:00

Clinical study seeks to validate dyskinesia clinical scales, lowering hurdle to industry investment in new treatments NEW YORK, Dec. 21 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's...

2009-12-21 07:00:00

SAN DIEGO, Dec. 21 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development. The first trial in human subjects, NBI-98854-0801, was a single ascending dose trial in healthy male volunteers conducted in Canada under an approved Clinical Trial Application (CTA) with Health Canada. Preliminary data have now been reviewed; NBI-98854 was...

2009-12-14 07:30:00

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today. ZYPREXA RELPREVV, a long-acting intramuscular injection, sustains the delivery of olanzapine for up to four weeks. Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics...

2009-12-10 06:57:00

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week. An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's...

2009-09-09 07:00:00

WILMINGTON, N.C., Sept. 9 /PRNewswire/ -- Wilmington Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) has granted marketing approval for METOZOLV((TM)) ODT (metoclopramide HCl), an orally disintegrating formulation of metoclopramide for the treatment of gastroesophageal reflux disease (GERD) and diabetic gastroparesis. Wilmington has licensed METOZOLV ODT to Salix Pharmaceuticals, Inc., a specialty pharmaceutical company with a focus on gastrointestinal...

2009-08-14 11:04:27

Schering-Plough Corp.'s asenapine has been cleared for sale as a treatment for schizophrenia and bipolar disorder in adults, U.S. authorities said. The drug is to be made available later this year and marketed under the name Saphris, the Food and Drug Administration said. Saphris is the first psychotropic drug to receive initial approval to treat both mental disorders, Schering-Plough officials said. Saphris is the first product from Schering-Plough's 2007 acquisition of Organon Biosciences....

2009-08-14 07:30:00

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved SAPHRIS(R) (asenapine) sublingual tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. SAPHRIS can be used as a first-line treatment and is the first psychotropic drug to receive initial approval for both of these indications simultaneously....

370572c9a414d9bd74461f1845d6423a1
2009-02-27 11:12:08

The US Food and Drug Administration is requiring makers of the heartburn drug Reglan to add a "black box" warning to inform patients that long term or high doses of the drug have been linked to involuntary movement throughout the body. More than 2 million Americans use the drugs to treat gastroesophageal reflux disease and other stomach problems, said the FDA. However, they warn that chronic use can cause tardive dyskinesia "“ characterized by uncontrollable repetitive movements of the...

2009-02-26 14:42:32

The U.S. Food and Drug Administration is ordering manufacturers of the drug metoclopramide to add a boxed warning about the drug's side effects. The FDA said the drug, used to treat gastrointestinal disorders, is sold as tablets, syrups and injections as Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide Oral Solution and Reglan Injection. The federal agency said more than two million U.S. residents use the products. FDA officials said the boxed warning must be added to the...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related